Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 13/20 | 0.56 |
| ▸ | PPARA | Q07869 | 13/20 | 0.56 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.46 |
| ▸ | AR | P10275 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
| ▸ | NOS2 | P35228 | 1/20 | 0.40 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4142305 | 1.00 | PPARG (0.56) | PPARGPPARAMRGPRX4ARSMN1; SMN2 | |
| SCHEMBL4141553 | 0.87 | AR (0.43) | PPARGPPARAMRGPRX4ARCYP2D6 | |
| SCHEMBL4135704 | 0.82 | MRGPRX4 (0.46) | PPARGPPARAMRGPRX4ARCYP2D6 | |
| SCHEMBL4145263 | 0.82 | MRGPRX4 (0.46) | PPARGPPARAMRGPRX4ARCYP2D6 | |
| SCHEMBL4133079 | 0.81 | PPARG (0.52) | PPARGPPARAAR | |
| SCHEMBL4489988 | 0.81 | PPARG (0.52) | PPARGPPARAAR | |
| SCHEMBL4140884 | 0.81 | PPARG (0.52) | PPARGPPARAAR | |
| SCHEMBL5985059 | 0.79 | MRGPRX4 (0.44) | MRGPRX4AR | |
| SCHEMBL14437655 | 0.79 | AR (0.47) | MRGPRX4ARSMN1; SMN2CYP2D6 | |
| SCHEMBL27376804 | 0.79 | AR (0.52) | MRGPRX4ARCYP2D6SLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7507860-B2 | Androgen modulators | PFIZER INC. (US) | 2009-03-24 | — | — | US | claimed |
| US-20090192202-A1 | ANDROGEN MODULATORS | PFIZER INC | 2009-07-30 | — | — | US | disclosed |
| US-7507860-B2 | Androgen modulators | PFIZER INC. (US) | 2009-03-24 | — | — | US | disclosed |
| US-20070197641-A1 | Androgen modulators | HU LAIN-YEN | 2007-08-23 | — | — | US | disclosed |
| EP-1737813-A1 | ANDROGEN MODULATORS | Warner-Lambert Company LLC (US) | 2007-01-03 | — | — | EP | disclosed |
| WO-2005100305-A1 | ANDROGEN MODULATORS | WARNER-LAMBERT COMPANY LLC (US) | 2005-10-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197641-A1 | Androgen modulators | AR, NR5A1, SHBG | PPARG 173/4885PPARA 203/4885MRGPRX4 1400/4885 |
| US-20090192202-A1 | ANDROGEN MODULATORS | AR, NR5A1, SHBG | PPARG 173/4885PPARA 203/4885MRGPRX4 1400/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.